Head-to-head evidence
itepekimab vs tozorakimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: IL-33 · full Chronic Obstructive Pulmonary Disease pipeline
itepekimab
Developed by Sanofi and partners
NCT04751487 · Phase 3 · completed
This was a large, randomized, quadruple-masked, placebo-controlled trial with a clinical primary endpoint: the annualized rate of moderate or severe COPD exacerbations. Because the registry has not posted the primary comparison results, it is not possible to determine whether the endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
tozorakimab
Developed by AstraZeneca
NCT06040086 · Phase 3 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 1,454 participants, and evaluated a clinical exacerbation outcome. However, no primary endpoint results or statistical comparison are available, so the treatment effect cannot yet be judged.
Next expected readout: December 2028 · NCT07566195 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: itepekimab's landscape · tozorakimab's landscape